KalVista Pharmaceuticals (KALV) Cash from Operations Growth (3y) (2019 - 2025)
KalVista Pharmaceuticals (KALV) Cash from Operations Growth (3y) (2019 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,908.96 Bn | 1,908.90 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 474.03 Bn | 469.24 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 34.32% |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn | -33.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -33.82% |
| Apr 30, 2025 | -14.64% |
| Oct 31, 2024 | -26.58% |
| Jul 31, 2024 | -31.38% |
| Apr 30, 2024 | -11.00% |
| Jan 31, 2024 | -53.75% |
| Oct 31, 2023 | -35.60% |
| Jul 31, 2023 | -95.31% |
| Apr 30, 2023 | -21.51% |
| Jan 31, 2023 | 10.85% |
| Oct 31, 2022 | -38.13% |
| Jul 31, 2022 | -26.35% |
| Apr 30, 2022 | -36.60% |
| Jan 31, 2022 | -9.02% |
| Oct 31, 2021 | -30.54% |
| Jul 31, 2021 | -41.86% |
| Apr 30, 2021 | -22.86% |
| Jan 31, 2021 | -31.40% |
| Oct 31, 2020 | -3.09% |
| Jul 31, 2020 | 6.91% |